Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta reported a Q2 2026 net loss of $40.4 million, or $0.54 per share, widening from a loss of $23.0 million in the prior year period as R&D investments increased to $29.0 million. The company is advancing its NKX019 autoimmune trials, Ntrust-1 and Ntrust-2, with ongoing enrollment at the 4 billion cell dose level and outpatient dosing now underway at community sites.
Key figures
- Net loss
- 40400000
- Ga expense
- 14100000
- Rd expense
- 29000000
- Cash balance
- 243200000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.